Nurix Therapeutics Stock Today
| NRIX Stock | USD 14.08 0.18 1.29% |
PerformanceVery Weak
| Odds Of DistressLow
|
Nurix Therapeutics is trading at 14.08 as of the 20th of March 2025; that is 1.29 percent increase since the beginning of the trading day. The stock's open price was 13.9. Nurix Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. The company has 75.89 M outstanding shares of which 11.36 M shares are now shorted by private and institutional investors with about 16.03 trading days to cover. More on Nurix Therapeutics
Moving together with Nurix Stock
Moving against Nurix Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Nurix Stock Highlights
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Nurix Therapeutics (NRIX) is traded on NASDAQ Exchange in USA. It is located in 1700 Owens Street, San Francisco, CA, United States, 94158 and employs 286 people. Nurix Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.06 B. Nurix Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 75.89 M outstanding shares of which 11.36 M shares are now shorted by private and institutional investors with about 16.03 trading days to cover.
Nurix Therapeutics currently holds about 344.48 M in cash with (172.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.31.
Check Nurix Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Nurix Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nurix Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nurix Therapeutics. Please pay attention to any change in the institutional holdings of Nurix Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Nurix Ownership Details
Nurix Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Nurix Therapeutics market risk premium is the additional return an investor will receive from holding Nurix Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (0.59) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | 0.8338 |
Nurix Stock Against Markets
Nurix Therapeutics Corporate Management
| Stefani Wolff | COO Devel | Profile | |
| Christopher Phelps | Senior Discovery | Profile | |
| Christine JD | Secretary Officer | Profile | |
| John Kuriyan | Founder Board | Profile | |
| JD Esq | VP Counsel | Profile | |
| Cristiana Guiducci | Senior Research | Profile |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.